

Impact of COVID-19 on cardiac procedure activity in England and associated 30-day mortality

Brief title: Impact of COVID-19 on cardiac procedure activity

Mohamed O. Mohamed, MRCP(UK)^{1,2}, Amitava Banerjee, DPhil³, Sarah Clarke, MD, FRCP⁴, Mark de Belder, MD FRCP⁵, Ashish Patwala, MD², Andrew T. Goodwin, PhD FRCS(CTh)^{5,6}, Chun Shing Kwok, PhD^{1,2}, Muhammad Rashid, PhD^{1,2}, Chris P Gale, PhD, FRCP^{7,8,9}, Nick Curzen, PhD, FRCP¹⁰, Mamas A. Mamas, DPhil^{1,2}

1. Keele Cardiovascular Research Group, Centre for Prognosis Research, Keele University, United Kingdom
2. Department of Cardiology, Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom
3. Institute of Health Informatics and Health Data Research UK, University College London, London, United Kingdom.
4. Royal Papworth NHS Foundation Trust, Cambridge, UK
5. National Institute for Cardiovascular Outcomes Research, Barts Health NHS Trust, London, UK
6. James Cook University Hospital, Middlesbrough, UK
7. Leeds Institute for Data analytics, University of Leeds, Leeds, UK
8. Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK
9. Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
10. Wessex Cardiothoracic Unit, Southampton University Hospital Southampton & Faculty of Medicine, University of Southampton, UK

Correspondence to:

Mamas A. Mamas
Professor of Cardiology
Keele Cardiovascular Research Group,
Centre for Prognosis Research,
Institute for Primary Care and Health Sciences,
Keele University, UK
mamasmamas1@yahoo.co.uk

Word count (exc. abstract): 2760

Key Words: COVID-19; procedures; cardiac; England; mortality

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020.
For permissions please email: journals.permissions@oup.com.

Abstract

Background: Limited data exists on the impact of COVID-19 on national changes in cardiac procedure activity, including patient characteristics and clinical outcomes before and during the COVID-19 pandemic.

Methods and Results: All major cardiac procedures (n=374,899) performed between 1st January and 31st May for the years 2018, 2019 and 2020 were analysed, stratified by procedure type and time-period (pre-COVID: January-May 2018 and 2019 and January-February 2020 and COVID: March-May 2020). Multivariable logistic regression was performed to examine the odds ratio (OR) of 30-day mortality for procedures performed in the COVID period.

Overall, there was a deficit of 45,501 procedures during the COVID period compared to the monthly averages (March-May) in 2018-2019. Cardiac catheterisation and device implantations were the most affected in terms of numbers (n=19,637 and n=10,453) whereas surgical procedures such as MVR, other valve replacement/repair, ASD/VSD repair and CABG were the most affected as a relative percentage difference (Δ) to previous years' averages. TAVR was the least affected (Δ -10.6%). No difference in 30-day mortality was observed between pre-COVID and COVID time-periods for all cardiac procedures except cardiac catheterisation (OR 1.25 95% confidence interval (CI) 1.07-1.47, p=0.006) and cardiac device implantation (OR 1.35 95% CI 1.15-1.58, p<0.001).

Conclusion: Cardiac procedural activity has significantly declined across England during the COVID-19 pandemic, with a deficit in excess of 45000 procedures, without an increase in risk of mortality for most cardiac procedures performed during the pandemic. Major restructuring of cardiac services is necessary to deal with this deficit, which would inevitably impact long-term morbidity and mortality.

Introduction

The COVID-19 pandemic has had a substantial influence on the provision of healthcare globally. This has been particularly evident in across cardiac services, given the reliance on multidisciplinary teams and the need for intensive care unit (ICU) bed availability. Patients with cardiovascular disease (CVD) were also subject to stricter isolation measures due to their increased risk of COVID-related death.¹⁻⁵ While there have been multiple reports indicating a reduction in the volume of different cardiac procedures, these have been based on single-centre experiences or examination of specific procedures,^{3, 6-9} rather than considering the broad spectrum of cardiac procedures from a national perspective. Therefore, little is known about the characteristics of patients undergoing procedures during the pandemic, and how these compare with those in the pre-COVID period. Furthermore, there is limited outcomes data for cardiac procedures performed prior to and during the COVID-19 pandemic.

The present study was designed to compare procedural activity between the pre-COVID and COVID period, as well as examine the associated 30-day mortality across cardiac procedures in England.

Methods

Data Source, Study Design and Population

All major cardiac and cardiothoracic inpatient and outpatient procedures performed in adults (aged ≥ 18 years) in England between 1st January and 31st May for each of the years 2018, 2019 and 2020 were extracted from Hospital Episode Statistics (HES) (NHS Digital). The HES dataset collects all data on all hospital admissions, outpatient appointments and accident and emergency attendances in NHS hospital.¹⁰ All elective and emergent/urgent hospital procedures studied included cardiac catheterisation, cardiac device implantations, percutaneous coronary intervention (PCI), percutaneous ablation, coronary artery bypass graft

(CABG) surgery, surgical and transcatheter aortic valve replacement (SAVR and TAVR, respectively), mitral valve replacement (MVR), other valve replacement/repair, and atrioseptal and ventriculoseptal defects (ASD and VSD respectively) repair. Given seasonality of procedural activity, we only included the first five months of each calendar year. Procedures were excluded if there was missing data for date and/or recording of death (n=230). Patients who received multiple procedures (n=35,984, 9,6% of final dataset) within a 30-day period were excluded in the analysis of 30-day mortality, as were deaths occurring more than 30 days after the procedure (n=20,928). 30-day mortality was collected via record linkage with the Office for National Statistics (ONS) Civil Registrations of Death dataset (up to date as of 7th July 2020).¹¹ The process of death certification and registration is a legal requirement in the United Kingdom, where a doctor who has seen the deceased within the last 14 days of life must complete a Medical Cause of Death Certificate unless a post-mortem examination is planned. International Classification of Diseases, tenth revision (ICD-10) codes were used to extract patient characteristics from HES, whereas OPCS Classification of Interventions and Procedures version 4.8 was used to identify procedures. A full list of the diagnosis codes used in the study is provided in **Supplementary Table 1**.

Outcomes

The co-primary outcomes were change in proportion (Δ) of monthly procedural activity between 2020 and earlier years (2018-2019) as well as the 30-day mortality rate for procedures performed before and after the COVID-19 pandemic.

Statistical Analysis

We examined the characteristics of patients undergoing the most common cardiac procedures over two time periods: 1st January-31st May 2018 and 2019; and 1st January-29th February 2020 (COVID period) and 1st March-31st May 2020 (COVID period). Age was normally distributed and, therefore summarized using mean and standard deviation (SD) and

compared using the t-test. Categorical variables were summarized as percentages and analysed using the chi squared (X^2) test or Fisher's exact test, where appropriate, and using the Kruskal-Wallis test for ordinal variables. Multivariable logistic regression models were fit to quantify the risk of 30-day mortality in the COVID period using the pre-COVID period as the reference category and are expressed as odds ratios (OR) with corresponding 95% confidence intervals (CI). Models were adjusted for age, sex, ethnicity, ST-elevation myocardial infarction (STEMI), non-ST-elevation acute coronary syndromes (NSTEMI), elective vs. inpatient admission, dyslipidaemia, smoking history, cardiac arrest, chronic heart failure, history of ischemic heart disease (IHD), myocardial infarction (MI), PCI, CABG surgery or cerebrovascular accident (CVA), atrial fibrillation (AF), ventricular tachycardia or fibrillation (VF/VT), dementia, chronic renal failure, hypertension, anaemia, chronic lung disease, diabetes mellitus, coagulopathies, liver disease, cancers, metastatic disease, peripheral vascular disease (PVD) and cardiogenic shock. Statistical analyses were performed using Stata 16 MP (College Station, TX).

Ethical Approval

The UK Secretary of State for Health and Social Care has issued a time limited Notice under Regulation 3(4) of the NHS (Control of Patient Information Regulations) 2002 (COPI) to share confidential patient information. The study complies with the Declaration of Helsinki. This work was part of a work stream endorsed by the Scientific Advisory Group for Emergencies (SAGE), the body responsible for ensuring timely and coordinated scientific advice is made available to UK government decision makers. SAGE supports UK cross-government decisions in the Cabinet Office Briefing Room (COBR) and by NHS England, which oversees commissioning decisions in the NHS, and NHS Improvement, which is responsible for overseeing quality of care in NHS hospitals.

Patient and Public Involvement

Patient and public were not involved because this study was to analyse routinely collected mortality and procedural data.

Results

A total of 374,899 cardiac procedures were performed between 1st January and 31st May 2018 to 2020 in England. The most commonly performed procedure was cardiac catheterisation (n=152,656), followed by cardiac device implantation (n=109,435), PCI (n=90,245), percutaneous ablation (n=22,903), CABG (n=18,030), SAVR (n=10,400), TAVR (n=5,664), MVR (n=4,774), other valve replacement/repair (n=1,400) and ASD/VSD repair (n=1,324).

Procedural activity

Overall, there was little change in procedural activity per 100,000 population in January and February 2020 compared with the corresponding monthly averages in 2018-2019, with an observed increase in some procedures (TAVR: Δ 24.6 and 32.3% respectively, other valve replacement/repair: Δ 5.6 and 16.7%, ASD/VSD repair: Δ 2.7 and 3.2%) and a decline in others (cardiac catheterisation: Δ -6.5 and -7.3%, CABG: Δ -4.0 and -9.1%, cardiac devices: Δ -8.8 and -9.7%). (**Table 1, Figure 1**)

There was a decline in numbers of all procedures performed between March and May 2020 compared with the 2018-2019 average for these months (total deficit: 45,501 procedures) (**Table 1**). Cardiac catheterisation and device implantations were the most affected in terms of numbers (n=19637 and n=10453) whereas surgical procedures such as MVR, other valve replacement/repair, ASD/VSD repair and CABG were the most affected as a relative percentage to previous years' averages. TAVR was the least affected (Δ -10.6%, 116 procedures). The decline in procedural activity was most pronounced in April and May 2020

(up to Δ -89.7%), with the least affected procedures being cardiac device implantation (Δ -52.8% to -56.8%), PCI (Δ -36.0 to -41.2%) and TAVR (Δ -18.1 to -35.4%). (**Table 1**)

Patient characteristics

In comparison with the pre-COVID period, patients undergoing certain procedures (PCI, cardiac catheterisation, CABG, TAVR and SAVR) were younger, whereas those undergoing percutaneous ablation and cardiac device implantation were older. (**Tables 2a and 2b**) Those undergoing PCI, cardiac catheterisation, MVR and CABG during the COVID period were more likely to be males compared to pre-COVID. Furthermore, there were fewer patients from Asian ethnic background during the COVID period amongst all procedural groups except other valve replacement/repair.

30-day mortality

While there was no difference in unadjusted rates of 30-day mortality for the majority of procedures performed in the pre-COVID and COVID time periods (**Table 3**), 30-day mortality was higher during the COVID period for patients undergoing cardiac catheterisation (1.6% vs. 1.1%, $p < 0.001$), ASD/VSD repair (9.1% vs. 1.4%, $p = 0.002$), percutaneous ablation (0.5% vs. 0.2%, $p = 0.037$) and cardiac device implantation (2.0% vs. 1.4%, $p < 0.001$). (Supplementary Figure 1).

After adjustment for baseline differences, there was no difference in 30-day mortality between pre-COVID and COVID time periods, except in those undergoing cardiac catheterisation and cardiac device implantation, who had increased odds of 30-day mortality (OR 1.25 95% CI 1.07, 1.47, $p = 0.006$ and OR 1.35 95% CI 1.15, 1.58, $p < 0.001$ respectively).

(**Table 4, Figure 2**)

Discussion

We present the first study to examine the impact of COVID-19 on procedural activity and subsequent mortality for all common cardiac procedures from a national perspective. This

study presents several important findings. First, we observe a substantial decline in all cardiac procedures performed between March and May 2020 compared to the same time period in earlier years (2018-2019), with certain procedures being more affected than others. We report a total deficit of more than 45,000 cardiac procedures over the COVID period (March-May 2020) compared with previous years. Second, we report minor age and ethnic differences in patient characteristics for the majority of cardiac procedures performed before and after the COVID-19 pandemic. Finally, we show that there was no difference in 30-day mortality between the pre-COVID and COVID periods for the majority of procedures, except in cardiac catheterisation and device implantation procedural groups that were associated with increased mortality.

The COVID-19 pandemic has led to substantial operational changes in healthcare delivery, especially among procedural specialties. Many professional societies recommended cancellation of elective procedures particularly in high-risk patients due to their increased risk of contracting COVID-19 and their increased risk of mortality, mainly due to factors such as prolonged hospital admission, the invasive nature of certain procedures, aerosol-generating nature of procedures, and the potential need for ICU resources that have been otherwise prioritised for COVID-19 cases.^{1, 2, 4, 12-18} As such, procedural activity has reportedly declined in many institutions.^{3, 4, 19} Although some studies or surveys^{3, 4, 19} have examined procedural activity in the COVID era, these mainly included specific centres (e.g. large tertiary facilities) or healthcare systems (e.g. Veterans Affairs (VA) only), early phases of the pandemic (e.g. up to April 2020), or specific procedures (e.g. PCI) without comparison between different procedure types.^{4, 7, 8, 19, 20} It is therefore, unclear which procedures were most affected nationally, the implications of such changes in activity and whether the outcomes of those who underwent cardiac procedures during the COVID-19 pandemic were worse compared with the pre-COVID era.

Waldo et al. reported a reduction in both elective and urgent PCI procedures in the VA healthcare system between 1st March and 27th June 2020 compared with the same time period in 2019 (3,859 to 2,192).⁶ While these findings are insightful, they were based on a relatively small number of PCI procedures from a single healthcare system that do not reflect national practice, and do not inform us of differences in outcomes between the two time periods. Another study by Lazaros et al. demonstrated a decline in cardiac surgery procedure activity in 2 large volume hospitals in Greece between 12th March and 7th May 2020 compared with the same time period in 2019 (246 vs. 84 procedures), especially for elective cases, with a relative rise in emergent procedures.⁸ However, their analysis was based on a small number of very specific procedure types, and did not look at postoperative outcomes for these time periods. Our findings demonstrate a substantial decline all cardiac procedural activity across England during the COVID period, even before the start of national lockdown (23rd March 2020). The greatest decline in procedure rates was observed amongst surgical procedures including MVR, other valve replacement/repair, ASD/VSD repair and CABG, whereas cardiac catheterisation and device implantations were the most affected in terms of absolute numbers.

Although there were certain age and ethnic differences between patients undergoing certain procedures in the pre-COVID and COVID time periods, the majority of characteristics were largely similar, suggesting that all individuals were affected. We found no difference in 30-day mortality between COVID and pre-COVID time periods for all cardiac procedures, except cardiac catheterisation and device implantations that were associated with increased odds of 30-day mortality, even after adjustment for baseline differences. The increased mortality amongst cardiac catheterisation and device implantation procedures could be due to residual confoundment, given that procedural characteristics were not captured in HES and, therefore, not adjusted for. This may be relevant for where higher risk patients prior to COVID underwent non-invasive assessment for coronary artery disease with procedures such as cardiac

CT, and during the COVID period, such patients were managed with an invasive approach to avoid close proximity to patients potentially infected with COVID-19 undergoing CT examinations. Similarly, only the most urgent device implantations are likely to have been performed during the COVID period, reflecting a higher risk cohort. Further work is required to define the cause of the increases in mortality in these patient groups, particularly whether the deaths were related to procedural complications or COVID-19 in the community.

Our findings raise important questions regarding the outcomes of patients whose interventions were deferred, especially those who are more frail or with a greater burden of comorbidities. Although difficult to quantify, the indirect burden of COVID-19 on morbidity and mortality of patients with cardiovascular disease whose interventions were deferred may exceed the direct effect of the infection in terms of mortality. For example, the one-year mortality of untreated symptomatic severe aortic stenosis (AS) is as high as 44%^{21,22} Similarly, severe untreated mitral stenosis is associated with high morbidity and mortality.²³ Therefore, timely interventions for such patients are crucial, and without a major restructure of health services to deal with the current backlog/deficit in procedural activity, which is quite significant in our national cohort, we are likely to observe an impact on their long-term morbidity and mortality. There has been limited guidance on the safe reintroduction of cardiovascular services during the pandemic, and this was primarily based on expert opinion.^{16 24} Guidance from the North American Society Leadership recommend measures such as pre-procedural physical distancing wherever possible, COVID-19 screening, and availability of personal protective equipment (PPE) as well as close collaboration with regional public health officials.²⁴ Prachand et al. proposed the medically-necessary time-sensitive (MeNTS) scoring system, based on 21 factors (patient, procedural, and disease-related), as a means of prioritising time-sensitive procedures while taking into account resource limitations during the COVID-19 pandemic.¹⁶ Despite its inherent limitations as the authors have acknowledged, including the

allocation of equal weighting to all 21 factors and lack of consideration of the patient's COVID status, the MeNTS score highlights the need for more refined scoring systems to objectively assess patient risk and the availability of resources and safely resume elective as well as semi-urgent procedural activity. Furthermore, several contingency measures could be employed to deal with the backlog in waiting lists such as seven-day working patterns in major centres, the collaboration with private healthcare institutions for bed availability, as well as recently retired operators who may be willing to temporarily return to practice. This is even more crucial in the event of further resurgence of COVID-19 outbreaks that would further increase the pressure on healthcare systems and continually growing waiting lists.

Limitations

There are several limitations to the present study. First, the observational nature of our analysis means that the observed associations do not necessarily infer causality. Second, while HES captures a significant amount of patient characteristics, factors such as the overall comorbid burden and frailty status cannot be objectively fully assessed using administrative data. Furthermore, certain procedural characteristics as well as pharmacological data were not available in HES, and therefore were not adjusted for. Finally, while we have demonstrated similar 30-day mortality in the pre-COVID and COVID eras for most procedures, these outcomes may differ significantly on longer follow up.

Conclusions

The COVID-19 pandemic resulted in a significant decline of all major cardiac procedural activity across England, with the most affected procedures being CABG, mitral and other valvular repairs/replacements, ASD/VSD repair as well as cardiac catheterisation and device implantations. Adjusted 30-day mortality was similar in the pre-COVID and COVID time periods for all cardiac procedures except cardiac catheterisation and device implantations.

Major operational changes are warranted to deal with the deficit in procedural activity and anticipated growth in waiting lists that could impact longer-term morbidity and mortality.

Acknowledgments

The authors acknowledge Tony Burton, Courtney Stephenson, Sion Philpott-Morgan and Kampreet Sandhu from NHS Digital, and Professor John Deanfield from University College London for providing and creating the secure environment for data hosting and for analytical support.

Contributorship statement

Mamas A. Mamas (MAM) and Mohamed O. Mohamed (MOM) were responsible for the study design and concept. MOM performed the data cleaning and analysis. MOM wrote the first draft of the manuscript, MAM provided senior supervision, and all authors contributed to the critical editing of the paper.

Disclosure statement

The authors report no conflicts of interest, financial disclosures or relationship with the industry.

Data availability statement

The data underlying this article cannot be shared publicly for the privacy of individuals included in the study as per restrictions in our data access agreement with NHS Digital.

References:

1. Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system. *Nature Reviews Cardiology* 2020;**17**(5):259-260.
2. Patel V, Jimenez E, Cornwell L, Tran T, Paniagua D, Denktas Ali E, Chou A, Hankins Samuel J, Bozkurt B, Rosengart Todd K, Jneid H. Cardiac Surgery During the Coronavirus Disease 2019 Pandemic: Perioperative Considerations and Triage Recommendations. *Journal of the American Heart Association* 2020;**9**(13):e017042.
3. Gaudino M, Chikwe J, Hameed I, Robinson NB, Fremes Stephen E, Ruel M. Response of Cardiac Surgery Units to COVID-19. *Circulation* 2020;**142**(3):300-302.
4. Marco R, Davide C, Stephan W, Andreas B, Dariusz D. Impact of the COVID-19 pandemic on interventional cardiology practice: results of the EAPCI survey. *EuroIntervention* 2020;**16**(3):247-250.
5. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q, Huang H, Yang B, Huang C. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. *JAMA Cardiology* 2020;**5**(7):802-810.
6. Waldo SW, Plomondon ME, O'Donnell CI, Heidenreich PA, Riatt MH, Ballard-Hernandez J, Ortiz J, Varosy PD, Vidovich MI, O'Donnell CJ, Schofield R. Trends in cardiovascular procedural volumes in the setting of COVID-19: Insights from the VA clinical assessment, reporting, and tracking program. *Catheterization and Cardiovascular Interventions* 2020;**n/a**(n/a).
7. DeFilippis EM, Sinnenberg L, Reza N, Givertz MM, Kittleson MM, Topkara VK, Farr MA. Trends in US Heart Transplant Waitlist Activity and Volume During the Coronavirus Disease 2019 (COVID-19) Pandemic. *JAMA Cardiol* 2020.
8. Lazaros G, Oikonomou E, Theofilis P, Theodoropoulou A, Triantafyllou K, Charitos C, Charalambous G, Papanikolaou A, Gastouniotis I, Siasos G, Vlachopoulos C, Tousoulis D. The impact of COVID-19 pandemic on adult cardiac surgery procedures. *Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese* 2020:S1109-9666(20)30161-5.
9. Bollmann A, Pellissier V, Hohenstein S, König S, Ueberham L, Meier-Hellmann A, Kuhlen R, Thiele H, Hindricks G, Helios hospitals G. Cumulative hospitalization deficit for cardiovascular disorders in Germany during the Covid-19 pandemic. *European Heart Journal - Quality of Care and Clinical Outcomes* 2020.
10. *Hospital Episode Statistics (HES)*. <https://digital.nhs.uk/data-and-information/data-tools-and-services/data-services/hospital-episode-statistics>.
11. (ONS) OfNS. Coronavirus (COVID-19) roundup. In; 2020.
12. Welt FGP, Shah PB, Aronow HD, Bortnick AE, Henry TD, Sherwood MW, Young MN, Davidson LJ, Kadavath S, Mahmud E, Kirtane AJ. Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From the ACC's Interventional Council and SCAI. *J Am Coll Cardiol* 2020;**75**(18):2372-2375.
13. Mohamed Abdel Shafi A, Hewage S, Harky A. The impact of COVID-19 on the provision of cardiac surgical services. *Journal of Cardiac Surgery* 2020;**35**(6):1295-1297.
14. Senni M. COVID-19 experience in Bergamo, Italy. *European Heart Journal* 2020;**41**(19):1783-1784.
15. Hassan A, Arora RC, Adams C, Bouchard D, Cook R, Gunning D, Lamarche Y, Malas T, Moon M, Ouzounian M, Rao V, Rubens F, Tremblay P, Whitlock R, Moss E, Légaré JF. Cardiac Surgery in Canada During the COVID-19 Pandemic: A Guidance Statement From the Canadian Society of Cardiac Surgeons. *Can J Cardiol* 2020;**36**(6):952-955.

16. Prachand VN, Milner R, Angelos P, Posner MC, Fung JJ, Agrawal N, Jeevanandam V, Matthews JB. Medically Necessary, Time-Sensitive Procedures: Scoring System to Ethically and Efficiently Manage Resource Scarcity and Provider Risk During the COVID-19 Pandemic. *Journal of the American College of Surgeons* 2020;**231**(2):281-288.
17. Cardiology. TESf. (2020) ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic.
18. Curzen N. An Extended Statement by the British Cardiovascular Intervention Society President Regarding the COVID-19 Pandemic. *Interventional cardiology (London, England)* 2020;**15**:e01-e01.
19. Ahmed M Adlan VGL, Gurpreet Dhillon, Hibba Kurdi, Gemina Doolub, Nadir Elamin, Amir Aziz, Sanjay Sastry, Gershan Davis. Impact of COVID-19 on primary percutaneous coronary intervention centres in the UK. *The British Journal of Cardiology* 2020;**27**:51-54.
20. Martin GP, Curzen N, Goodwin A, Nolan J, Balacumaraswami L, Ludman P, Kontopantelis E, Wu J, Gale CP, de Belder M, Mamas MA. Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England. *medRxiv* 2020:2020.08.05.20168922.
21. Gardin JM, Kaplan KJ, Meyers SN, Talano JV. Aortic stenosis: can severity be reliably estimated noninvasively? *Chest* 1980;**77**(2):130-1.
22. Shareghi S, Rasouli L, Shavelle DM, Burstein S, Matthews RV. Current results of balloon aortic valvuloplasty in high-risk patients. *J Invasive Cardiol* 2007;**19**(1):1-5.
23. Pasca I, Dang P, Tyagi G, Pai RG. Survival in Patients with Degenerative Mitral Stenosis: Results from a Large Retrospective Cohort Study. *J Am Soc Echocardiogr* 2016;**29**(5):461-9.
24. Wood DA, Mahmud E, Thourani VH, Sathananthan J, Virani A, Poppas A, Harrington RA, Dearani JA, Swaminathan M, Russo AM, Blankstein R, Dorbala S, Carr J, Virani S, Gin K, Packard A, Dilsizian V, Légaré J-F, Leipsic J, Webb JG, Krahn AD. Safe Reintroduction of Cardiovascular Services During the COVID-19 Pandemic: From the North American Society Leadership. *The Annals of Thoracic Surgery* 2020;**110**(2):733-740.

Figures captions and legends:

Figure 1. Trend of procedural activity (January-May) over the study years

Legend: ASD/VSD: atrioseptal and ventriculoseptal defect; CABG: coronary artery bypass grafting; MVR: mitral valve replacement; PCI: percutaneous coronary intervention; SAVR: surgical aortic valve replacement; TAVR: transcatheter aortic valve replacement

Figure 2. Adjusted odds of 30-day mortality according to procedure type^a

Legend: ASD/VSD: atrioseptal and ventriculoseptal defect; CABG: coronary artery bypass grafting; MVR: mitral valve replacement; PCI: percutaneous coronary intervention; SAVR: surgical aortic valve replacement; TAVR: transcatheter aortic valve replacement

^a reference category is January-May for years 2018 and 2019, and January-February 2020

^b Perfect predictor variable

^c no deaths occurred

Table 1. Cardiac procedural volumes (January-May) according to time period

	Year	January n (per 100,000)	% change ^b	February n (per 100,000)	% change ^b	March n (per 100,000)	% change ^b	April n (per 100,000)	% change ^b	May n (per 100,000)	% change ^b	Total deficit in March-May 2020 (n (% change))
Cardiac catheterisation	2018-2019 ^a	12139 (20.66)		11290 (19.22)		11768 (20.03)		11736 (19.98)		12571 (21.4)		
	2020	11313 (19.03)	-6.5	10335 (17.39)	-7.3	7652 (12.87)	-34.3	3066 (5.16)	-73.1	4500 (7.57)	-62.8	19637 (56.3)
PCI	2018-2019 ^a	6531 (11.12)		5903 (10.05)		6693 (11.39)		6501 (11.07)		6720 (11.44)		
	2020	6551 (11.02)	-0.9	5982 (10.06)	-0.9	5299 (8.91)	-20.6	3763 (6.33)	-41.2	4311 (7.25)	-36.0	6257 (31.9)
CABG	2018-2019 ^a	1413 (2.41)		1367 (2.33)		1376 (2.34)		1451 (2.47)		1531 (2.61)		
	2020	1342 (2.26)	-9.1	1284 (2.16)	-4.0	802 (1.35)	-43.6	245 (0.41)	-82.4	323 (0.54)	-78.0	2860 (67.6)
ASD/VSD Repair	2018-2019 ^a	105 (0.18)		94 (0.16)		98 (0.17)		107 (0.18)		113 (0.19)		
	2020	114 (0.19)	2.7	96 (0.16)	3.2	58 (0.1)	-44.4	20 (0.03)	-83.8	16 (0.03)	-81.8	217 (69.8)
TAVR	2018-2019 ^a	350 (0.6)		306 (0.52)		317 (0.54)		369 (0.63)		341 (0.58)		
	2020	483 (0.81)	24.6	466 (0.78)	32.2	447 (0.75)	20.0	251 (0.42)	-35.4	308 (0.52)	-18.1	119 (10.6)
SAVR	2018-2019 ^a	858 (1.46)		771 (1.31)		757 (1.29)		805 (1.37)		882 (1.5)		
	2020	754 (1.27)	-11.8	698 (1.17)	-12.0	464 (0.78)	-43.3	187 (0.31)	-76.0	224 (0.38)	-73.0	1527 (63.6)
MVR	2018-2019 ^a	396 (0.67)		341 (0.58)		326 (0.55)		416 (0.71)		446 (0.76)		
	2020	377 (0.63)	-1.6	337 (0.57)	0.9	217 (0.37)	-38.3	58 (0.1)	-85.1	63 (0.11)	-83.8	810 (70.6)
Other valves	2018-2019 ^a	112 (0.19)		98 (0.17)		90 (0.15)		128 (0.22)		145 (0.25)		
	2020	127 (0.21)	16.7	115 (0.19)	5.6	51 (0.09)	-45.5	15 (0.03)	-85.4	12 (0.02)	-89.7	252 (76.4)
Percutaneous Ablation	2018-2019 ^a	1777 (3.02)		1657 (2.82)		1741 (2.96)		1671 (2.84)		1845 (3.14)		
	2020	1894 (3.19)	0.5	1695 (2.85)	3.8	1199 (2.02)	-32.0	190 (0.32)	-88.8	476 (0.80)	-73.9	3369 (64.4)
Cardiac Devices	2018-2019 ^a	8700 (14.81)		8026 (13.66)		8180 (13.92)		8300 (14.13)		8695 (14.8)		
	2020	7708 (12.97)	-9.7	7081 (11.91)	-8.8	6469 (10.88)	-21.4	3752 (6.31)	-52.8	3585 (6.03)	-56.8	10453 (43.1)

^a average number of procedures over 2018 and 2019^b % change between 2018-2019 average and 2020, based on procedure frequency per 100,000 population

Table 2a. Patient characteristics of cardiology procedures according to time period

	Cardiac catheterisation (n=152656)			PCI (n=90245)			TAVR (n=5664)			Percutaneous Ablation (n=22903)			Cardiac Devices (n=109435)		
	Pre- COVID ^a (n=137438)	COVID ^b (n=15218)	p- value	Pre- COVID ^a (n=76872)	COVID ^b (n=13373)	p- value	Pre- COVID ^a (n=4658)	COVID ^b (n=1006)	p- value	Pre- COVID ^a (n=21038)	COVID ^b (n=1865)	p- value	Pre- COVID ^a (n=95629)	COVID ^b (n=13806)	p- value
Age, mean (SD)	66.2 (12.6)	65.7 (12.5)	<0.001	65.3 (12.5)	64.6 (12.5)	<0.001	80.6 (9.7)	75.9 (15.7)	<0.001	59.5 (15.5)	60.5 (15.5)	0.017	71.3 (15.0)	72.5 (14.5)	<0.001
Males	64.5	65.9	<0.001	74.6	75.9	0.002	54.5	57.7	0.065	61.2	62.5	0.305	66.5	67.2	0.130
Ethnicity			<0.001			<0.001			<0.001			0.916			<0.001
White	76.5	76.8		73.3	72.1		76.6	69.3		72.6	73.1		80.7	82.0	
Asian	6.6	5.3		7.7	6.8		2.2	1.7		2.2	2.0		3.8	2.8	
Black	1.6	1.3		1.0	0.9		0.6	0.3		1.0	1.0		1.3	1.1	
Other	15.3	16.6		17.9	20.2		20.6	28.7		24.2	23.8		14.2	14.2	
STEMI	3.0	4.8	<0.001	31.1	37.8	<0.001	0.1	0.0	0.255	0.1	0.1	0.695	1.6	1.5	0.321
NSTEMACS	15.7	19.3	<0.001	32.2	34.3	<0.001	1.2	1.3	0.813	0.2	0.3	0.539	5.3	3.8	<0.001
Dyslipidemia	33.6	30.8	<0.001	38.7	35.3	<0.001	25.6	23.1	0.096	12.2	11.2	0.199	20.9	16.4	<0.001
Cardiac arrest	0.2	0.3	0.016	0.7	0.6	0.150	0.7	0.5	0.542	0.0	0.0	0.346	0.5	0.5	0.568
Heart failure	15.4	15.4	0.818	15.3	15.8	0.053	27.7	24.4	0.024	13.3	18.0	<0.001	25.2	25.9	0.08
VF/VT	1.6	2.1	<0.001	2.7	3.6	<0.001	1.7	1.9	0.635	5.7	6.4	0.186	4.4	5.3	<0.001
AF	3.4	3.9	0.002	2.1	2.2	0.203	6.6	5.5	0.194	25.5	23.5	0.055	6.8	7.5	0.006
History of IHD	14.3	15.2	0.004	17.1	17.6	0.178	15.9	11.8	0.001	6.4	8.5	0.001	13.9	15.2	<0.001
Previous CABG	5.4	4.8	0.003	6.1	4.8	<0.001	12.0	7.9	<0.001	3.3	3.8	0.237	5.6	5.7	0.561
Dementia	0.4	0.3	0.259	0.5	0.4	0.214	1.5	0.6	0.021	0.2	0.1	0.214	1.7	1.8	0.394
Chronic renal failure	8.1	7.1	<0.001	7.5	6.6	<0.001	23.9	18.1	<0.001	3.6	4.9	0.003	11.0	11.4	0.155
Hypertension	54.8	53.9	0.048	55.2	52.9	<0.001	61.2	58.2	0.076	31.7	32.3	0.604	47.0	46.2	0.079
Anemias	2.1	1.8	0.05	2.0	1.6	0.009	10.3	8.3	0.063	1.0	0.9	0.79	4.9	4.0	0
Chronic lung disease	17.9	18.0	0.700	15.2	15.0	0.481	23.3	20.5	0.053	13.0	13.0	0.929	14.0	14.4	0.194
Diabetes	23.9	22.7	0.002	25.1	24.1	0.008	26.0	20.9	0.001	10.0	10.7	0.378	20.0	19.8	0.49
Coagulopathies	0.6	0.5	0.191	0.5	0.5	0.878	2.4	2.6	0.675	0.5	0.3	0.199	1.6	1.1	<0.001
Liver disease	1.5	1.8	0.012	1.1	1.1	0.433	2.5	3.8	0.029	0.7	1.3	0.006	1.3	1.3	0.916

	Cardiac catheterisation (n=152656)			PCI (n=90245)			TAVR (n=5664)			Percutaneous Ablation (n=22903)			Cardiac Devices (n=109435)		
	Pre- COVID ^a (n=137438)	COVID ^b (n=15218)	p- value	Pre- COVID ^a (n=76872)	COVID ^b (n=13373)	p- value	Pre- COVID ^a (n=4658)	COVID ^b (n=1006)	p- value	Pre- COVID ^a (n=21038)	COVID ^b (n=1865)	p- value	Pre- COVID ^a (n=95629)	COVID ^b (n=13806)	p- value
Metastatic disease	0.3	0.4	0.021	0.3	0.3	0.124	0.5	0.6	0.611	0.1	0.1	0.979	0.3	0.4	0.284
PVD	4.4	4.0	0.064	4.3	4.3	0.705	12.8	10.8	0.094	1.9	1.2	0.052	4.5	4.1	0.028
Cardiogenic shock	0.3	0.3	0.661	1.4	1.3	0.264	0.4	0.2	0.408	0.1	0.1	0.871	0.4	0.5	0.473
Cancers	1.7	1.7	0.651	1.8	1.5	0.056	3.5	4.3	0.234	0.7	0.9	0.495	2.1	2.2	0.236

^a January-May for years 2018 and 2019, and January-February 2020

^b March-May 2020

Table 2b. Patient characteristics of cardiothoracic procedures

	SAVR (n=10400)			MVR (n=4774)			Other valves (n=1400)			ASD VSD Repair (n=1324)			CABG (n=18030)		
	Pre-COVID ^a (n=9525)	COVID ^b (n=875)	p-value	Pre-COVID ^a (n=4436)	COVID ^b (n=338)	p-value	Pre-COVID ^a (n=1322)	COVID ^b (n=78)	p-value	Pre-COVID ^a (n=1230)	COVID ^b (n=94)	p-value	Pre-COVID ^a (n=16660)	COVID ^b (n=1370)	p-value
Age, mean (SD)	67.3 (13.7)	64.3 (16.2)	<0.001	64.9 (14.7)	63.9 (15.0)	0.250	61.2 (19.6)	57.5 (19.8)	0.112	48.9 (21.8)	52.8 (17.7)	0.141	66.8 (11.0)	66.0 (9.9)	0.006
Males	67.6	68.7	0.521	61.1	67.2	0.031	54.7	60.8	0.300	47.2	53.8	0.221	81.9	85.0	0.005
Ethnicity			0.016			0.155			0.037			0.814			<0.001
White	73.8	73.0		70.5	69.2		70.7	60.3		64.0	63.8		69.0	70.1	
Asian	2.9	1.3		4.6	2.4		4.7	5.1		5.4	3.2		7.2	4.1	
Black	1.0	0.8		1.8	2.1		1.4	5.1		2.0	2.1		0.7	1.1	
Other	22.3	24.9		23.0	26.3		23.2	29.5		28.7	30.9		23.1	24.7	
STEMI	0.4	1.0	0.005	1.0	0.9	0.793	0.2	1.3	0.09	3.4	8.5	0.012	4.7	5.5	0.199
NSTEACS	3.9	4.2	0.649	2.6	3.0	0.684	0.6	1.3	0.467	1.3	3.2	0.137	28.4	32.4	0.002
Dyslipidemia	35.6	31.2	0.008	23.4	19.2	0.077	18.6	21.8	0.484	12.0	8.5	0.307	55.6	54.2	0.311
Cardiac arrest	0.6	0.7	0.842	0.5	0.0	0.185	0.9	0.0	0.398	0.2	1.1	0.077	0.4	0.4	0.670
Heart failure	22.0	24.2	0.103	32.2	36.4	0.070	35.1	37.2	0.678	15.3	27.7	0.003	19.7	22.4	0.016
VF/VT	3.0	3.4	0.506	3.5	8.0	<0.001	4.1	10.3	0.01	3.1	5.3	0.240	2.7	2.7	0.999
AF	6.2	5.9	0.805	8.9	8.9	0.992	7.3	7.7	0.887	5.3	7.4	0.373	4.0	3.6	0.486
History of IHD	8.9	9.3	0.741	6.9	6.5	0.762	3.9	3.8	0.969	3.1	6.4	0.086	23.8	28.6	<0.001
Previous CABG	1.1	1.4	0.451	1.9	2.7	0.324	1.4	1.3	0.953	0.4	1.1	0.360	1.6	1.4	0.478
Dementia	0.2	0.0	0.155	0.2	0.0	0.465	0.2	0.0	0.731	0.1	0.0	0.782	0.2	0.1	0.339
Chronic renal failure	10.1	9.0	0.303	11.0	12.7	0.346	12.4	10.3	0.574	4.7	6.4	0.468	9.8	9.5	0.745
Hypertension	60.5	61.0	0.78	47.1	44.4	0.327	39.0	41.0	0.726	26.3	26.6	0.943	70.3	74.9	<0.001
Anemias	11.9	13.1	0.261	11.8	12.1	0.862	12.0	12.8	0.834	5.5	7.4	0.438	11.3	12.8	0.104
Chronic lung disease	16.5	19.2	0.043	16.9	15.7	0.554	14.5	14.1	0.918	11.4	9.6	0.593	15.4	16.9	0.138
Diabetes	19.3	18.1	0.365	10.5	9.2	0.446	9.4	10.3	0.797	6.9	11.7	0.084	31.5	30.9	0.659
Coagulopathies	5.6	4.8	0.33	6.4	4.4	0.151	8.2	5.1	0.336	3.4	5.3	0.336	2.9	2.4	0.318

	SAVR (n=10400)			MVR (n=4774)			Other valves (n=1400)			ASD VSD Repair (n=1324)			CABG (n=18030)		
	Pre- COVID ^a (n=9525)	COVID ^b (n=875)	p- value	Pre- COVID ^a (n=4436)	COVID ^b (n=338)	p- value	Pre- COVID ^a (n=1322)	COVID ^b (n=78)	p- value	Pre- COVID ^a (n=1230)	COVID ^b (n=94)	p- value	Pre- COVID ^a (n=16660)	COVID ^b (n=1370)	p- value
Liver disease	2.6	2.2	0.482	2.9	4.4	0.107	4.4	7.7	0.174	2.4	2.1	0.887	1.9	1.7	0.519
Metastatic disease	0.2	0.1	0.621	0.2	0.6	0.195	1.7	3.8	0.157	0.3	0.0	0.580	0.1	0.1	0.892
PVD	10.6	11.2	0.557	5.2	4.4	0.560	4.5	2.6	0.410	2.7	2.1	0.746	9.9	10.0	0.898
Cardiogenic shock	0.7	1.1	0.093	1.1	3.6	<0.001	1.1	2.6	0.224	1.7	3.2	0.299	0.6	1.1	0.049
Cancers	1.8	1.8	0.985	1.4	1.5	0.957	2.2	5.1	0.097	0.4	0.0	0.536	1.5	1.1	0.219

^a January-May for years 2018 and 2019, and January-February 2020

^b March-May 2020

Table 3. Crude rates of 30-day mortality according to procedure type

	2018-Feb 2020 (%)^a	March-May 2020 (%)	Total (%)	p-value
Cardiac catheterisation	1.1%	1.6%	1.2%	<0.001
PCI	2.7%	2.8%	2.7%	0.481
CABG	1.1%	1.8%	1.1%	0.328
ASD/VSD Repair	1.4%	9.1%	1.9%	0.002
TAVR	2.4%	2.1%	2.3%	0.687
SAVR	4.4%	6.9%	4.9%	0.326
MVR	6.2%	3.3%	5.8%	0.532
Other valves	2.3%	0% ^b	2.0%	0.799
Percutaneous Ablation	0.2%	0.5%	0.2%	0.037
Cardiac Devices	1.4%	2.0%	1.5%	<0.001

^a Included months are January through May for 2018 and 2019;

^b no deaths occurred

Table 4. Adjusted odds ratios (OR) of 30-day mortality during March-May 2020 according to procedure type^a


	OR [95% confidence interval]	p-value
Cardiac catheterisation	1.25 [1.07, 1.47]	0.006
PCI	1.02 [0.89, 1.16]	0.829
CABG	2.77 [0.85, 9.03]	0.090
ASD/VSD Repair	b	b
TAVR	0.85 [0.39, 1.84]	0.682
SAVR	1.64 [0.49, 5.40]	0.420
MVR	b	b
Other valve repair/replacement	c	c
Percutaneous Ablation	1.71 [0.73, 3.98]	0.215
Cardiac Devices	1.35 [1.15, 1.58]	<0.001

^a reference category is January-May for years 2018 and 2019, and January-February 2020


^b Perfect predictor variable

^c no deaths occurred


Cardiac Catheterisation




PCI




CABG




ASD/VSD Repair




MVR




SAVR




TAVR



Cardiac devices



Percutaneous Ablation



Other Valves

